Peripheral visual field constriction and night blindness are the main features of retinitis pigmentosa (RP). However, central vision is often impaired dramatically even in the early stages of the disease when macular complications such as cystoid macular oedema (CME) occur. The pathogenesis of RP-related CME is still not well explained. Therefore, several treatment alternatives such as topical, oral and systemic pharmacotherapy; laser photocoagulation and even vitreoretinal surgery are employed by the clinicians. In this review, we summarise the clinical data on intravitreal pharmacotherapeutic agents and focus mainly on the steroids and anti-vascular endothelial growth factor agents.

Retinitis pigmentosa (RP) is an inherited retinal dystrophy characterised with the progressive loss of photoreceptors. Night blindness together with the peripheral visual field loss is the most prominent clinical feature. Central vision is relatively spared up to the later stages of the disease process. However, when macular complications such as macular oedema arise, central vision is often dramatically impaired even in the early stages of the disease. The prevalence of cystoid macular oedema (CME) is reported to be 10–20% in the eyes of patients with RP.

The pathogenesis of RP-related CME is still unclear. Blood–retinal barrier (BRB) impairment, retinal pigment epithelium (RPE) pump disturbance, inflammation, autoimmunity and vitreoretinal interface changes may be among the potential causes of CME.

Fishman et al. examined 15 RP patients with vitreous fluorophotometry. All patients showed abnormally high concentrations of fluorescein within the vitreous which was a sign of BRB abnormality. Larsen et al. demonstrated that BRB leakage was markedly increased in six RP patients with the help of ocular spectrofluorometry. Vinores et al. investigated the immunohistochemical staining for albumin on paraffin sections of 22 normal and 29 RP eyes. Electron microscopic immunocytochemical staining for albumin was performed on additional six normal and nine RP-affected eyes. Two-thirds of the eyes with RP demonstrated extravascular albumin in the inner portion of the posterior retina. This was evident even in the absence of CME but eyes with CME showed extensive BRB failure. Küchle et al. analysed the BRB in patients with RP with a laser cell photometer in 56 eyes of 29 patients and found that aqueous flare values were higher in patients with RP than in controls; moreover, patients with RP-related CME had even higher values with a mean of 14.66 photon counts per millisecond compared with 9.65 for patients with RP but having no CME. RPE seems to lose polarised apical distribution in association with macular oedema and RP and cannot effectively pump out ions and fluid from the outer retina.

Autoimmune processes and/or inflammation can be deemed as the hallmark of RP-related CME. Spalton et al. examined 25 patients with RP and all patients had an excessive number of vitreous cells; six even had exudates in the pre-equatorial fundus indistinguishable from pars planitis. They suggested that this might be a general response noticed in many types of tapetoretinal degeneration in reaction to actually degenerating photoreceptors or RPE. Furthermore, Heckenlively et al. looked for the presence of antiretinal antibodies in a group of 30 consecutive patients with CME and RP, 30 consecutive patients with RP but without CME and 50 normal subjects. Twenty-seven (90%) of the patients with RP and CME had antiretinal protein antibody activity compared with three of 50 normal subjects (6%) and only four of 30 patients (13%) with RP but without coexistent CME.

Yoshida et al. studied the nature of inflammatory reaction in eyes of patients with RP. In 190 of 509 eyes (37.3%) with RP, "1+" (5–9 cells per field) or more cells were observed in the
anterior vitreous cavity. A strong inflammatory reaction with ‘2+’ cells (10–30 cells per field) was associated with younger age. The levels of various proinflammatory cytokines and chemokines including monocyte chemotactic protein-1 were increased both in the aqueous humour and vitreous fluid of RP patients compared with the levels in control patients.14

Vitreoretinal abnormalities can be a factor in the development of CME in RP patients.15–17 Kim et al.16 detected CME in 46 of 220 eyes with RP with the spectral domain optic coherence tomography (SD-OCT). Vitreomacular interface abnormalities including epiretinal membrane development and vitreomacular traction were evident in over 40% of patients and the presence of vitreoretinal abnormalities was significantly higher in eyes with CME than in eyes without CME (64.1% versus 36.8%). Spontaneous release of vitreoretinal traction may alleviate the RP-related CME as soon as the spontaneous resolution of traction occurs.17 It is also speculated that vitreoretinal abnormalities may induce a mechanical damage to the Muller cells that are an essential element for visual transduction and retinal homeostasis as Muller cells play an important role in the fluid dynamics.18,19

Treatment

Various treatment alternatives including topical (nonsteroidal anti-inflammatory agents, carbonic anhydrase inhibitors), oral agents (carbonic anhydrase inhibitors, steroids), grid laser photocoagulation and vitreoretinal surgery were utilised in the treatment of RP-related CME.11,20–25 In this review we focus on the intravitreal pharmacotherapy.

### Table 1: Intravitreal steroid administration in retinitis pigmentosa-related cystoid macular oedema

| Authors (year) | Study design | No. of eyes/cases | Agent            | Mean follow-up period (months) | Outcome                                                                 | Reinjection (eyes) | Conclusion                        |
|----------------|--------------|------------------|------------------|-------------------------------|--------------------------------------------------------------------------|-------------------|-----------------------------------|
| Saraiva et al. (2003) | Case report | 2/1              | 4 mg IVTA        | 8                             | Improvement in BCVA (1 of 2 eyes), improvement in CMT (all eyes)          | None               | Useful in some selected cases     |
| Ozdemir et al. (2005) | Case series | 5/5              | 4 mg IVTA        | 6.8                           | Improvement in BCVA (2 of 5 eyes), improvement in CMT (all eyes)         | 3                 | Despite good anatomic results, no BCVA improvement in some cases |
| Wang et al. (2006) | Case series | 4/2              | 4 mg IVTA        | 1                             | Improvement in BCVA and CMT (all eyes)                                   | NR                | A promising treatment option      |
| Scorilli et al. (2007) | Prospective nonrandomised comparative trial | 20/20   | 4 mg IVTA        | 12                            | No significant changes in BCVA, but significant improvement in CMT       | None               | Useful in selected cases but its efficacy seems limited |
| Srou et al. (2012) | Case series | 4/3              | 0.7 mg DEX implant | 6                             | Improvement in BCVA and CMT (all patients)                               | 2                 | A valuable treatment option       |
| Saatci et al. (2013) | Case report | 2/1              | 0.7 mg DEX implant | 7                             | Improvement in BCVA and CMT (all eyes)                                   | None               | A therapeutic option especially in cases unresponsive to other treatments |
| Ahl Hassan et al. (2013) | Case report | 1/1              | 0.7 mg DEX implant | 1                             | Improvement in BCVA and CMT                                              | NR                | Even provide anatomical and functional improvements in the fellow eye |
| Ahn et al. (2014) | Case report | 2/1              | 0.7 mg DEX implant | 12                            | Improvement in BCVA and CMT (all eyes)                                   | 2                 | Useful with limited efficacy      |
| Ornek et al. (2016) | Case report | 2/1              | 0.7 mg DEX implant | 6                             | Improvement in BCVA and CMT (all eyes)                                   | NR                | Rapid response in resistant CME cases |
| Mansour et al. (2017) | Retrospective case series | 45/34   | 0.7 mg DEX implant | 15.5                          | At month 3, visual acuity improved to 20/47 from the baseline of 20/81   | 14                | BCVA improved in half of patients at the fourth month but cataracts ensued with multiple injections |

BCVA = best corrected visual acuity; CME = cystoid macular oedema; CMT = central macular thickness; DEX = dexamethasone; IVTA = intravitreal triamcinolone; NR = not reported.
Intravitreal Pharmacotherapy in the Treatment of Retinitis Pigmentosa-related Cystoid Macular Oedema

Intravitreal steroids

Steroids exert their effect via several mechanisms such as reduction in synthesis and release of proinflammatory cytokines, suppression of the production and migration of inflammatory cells, and suppression of the autoimmune process and restoration of the integrity of BRB.26–30

The previous reports on intravitreal steroid administration in eyes with RP-related CME30–39 are summarised in Table 1. The treatment effect of dexamethasone implant can be seen in a case with bilateral RP-related CME (Figures 1 and 2).

The most important drawbacks in the use of intravitreal steroids in RP-related CME are temporary drug effect and risk of ocular hypertension and cataract formation especially with consecutive injections.30

Intravitreal anti-vascular endothelial growth factor agents

Intravitreal anti-vascular endothelial growth factor (VEGF) administration is shown to be very effective in VEGF-driven disease processes by reversing mainly the VEGF-driven BRB disruption.40,41

Salom et al.42 quantified the VEGF-A levels in aqueous humour of 16 eyes of 16 patients with RP. They found that aqueous VEGF-A levels were markedly lower in eyes with RP than in control patients. Strong et al.43 hypothesised that a localised VEGF production under pathologic conditions, for example by Müller cells, may contribute to CME formation in RP patients and this fact may also be the reason for the rarity of peripheral neovascularisation in eyes with RP. The previous reports on intravitreal anti-VEGF agent administered in eyes with RP-related CME43–49 are summarised in Table 2.

Intravitreal autologous bone marrow-derived haematopoietic stem cell transplantation

Siqueira et al.50 published a case with RP-related CME who received treatment with an intravitreal injection of autologous bone marrow-derived haematopoietic stem cell (auto-BMHSCT) and showed complete resolution of CME 7 days after the injection. This effect lasted for a month. Visual acuity was improved to 20/50 from 20/32. Macular sensitivity measured by the microperimetry was also improved. Authors speculated that auto-BMHSCT might restore the BRB via its paracrine effects and thereby provided the resolution of the oedema.

Comments

There is yet no proven treatment for RP-related CME and no randomised controlled studies with a sufficient number of patients have been performed. Intravitreal steroids and anti-VEGF agents are reported to have some effect on RP-related CME but the durability of treatment effect and the selection of agent (anti-VEGF or steroids) are highly controversial. Thereby, we intend to review the current status of the intravitreal pharmacotherapy in the treatment of RP-related CME and share some of the latest data with the ophthalmic community.

---

Table 2: Intravitreal anti-vascular endothelial growth factor administration in retinitis pigmentosa-related cystoid macular oedema

| Authors (year)          | Study design                  | No of eyes/cases | Agent                  | Mean follow-up period (months) | Outcome                                             | Reinjection (eyes) | Conclusion                          |
|-------------------------|-------------------------------|------------------|------------------------|-------------------------------|-----------------------------------------------------|-------------------|-------------------------------------|
| Melo et al.44 (2007)    | Case report                   | 2/2              | 1.25 mg bevacizumab    | 4                             | No improvement in BCVA and CMT                       | NR                | Ineffective                         |
| Yuzbasioğlu et al.46 (2009) | Prospective study             | 13/7             | 1.25 mg bevacizumab    | 10.2                          | Improvement in BCVA and CMT                          | 7                 | Effective                           |
| Querques et al.48 (2009) | Case report                   | 1/1              | 0.3 mg pegaptanib sodium | 4                             | Improvement in BCVA and none in CMT                  | NR                | May be beneficial in combination with acetazolamide |
| Artunay et al.47 (2009) | Prospective controlled interventional study | 15/15           | 0.5 mg ranibizumab    | 6                             | No significant changes in BCVA, significant change in CMT | NR                | A promising new therapeutic approach |
| Shah et al.48 (2009)    | Case report                   | 1/1              | 0.5 mg ranibizumab    | 6                             | No improvement in BCVA, improvement of CMT           | 1                 | Effective                           |
| Moustafa et al.49 (2015) | Case report                   | 1/1              | 0.5 mg aflibercept     | 6                             | Improvement in BCVA and CMT, no change in mfERG      | None              | Effective                           |
| Strong et al.50 (2016)  | Case report                   | 1/1              | 2 mg aflibercept      | 19                            | Improvement in BCVA and CMT                          | 1                 | Aflibercept may be more effective than other anti-VEGFs |

BCVA = best corrected visual acuity; CMT = central macular thickness; mfERG = multifocal electroretinogram; NR = not reported; VEGF = vascular endothelial growth factor.

---

Figure 2: Fifteen months following the three-dexamethasone implant administration

Colour pictures (A, B; please note that growing cataract is blurring the fundus appearance); optical coherence tomographic pictures of both eyes (C, D).
Review

Retinitis Pigmentosa

1. Hamel C, Retinitis pigmentosa, Orphanet J Rare Dis, 2006;1:40.
2. Masmor ME, Aguirre E, Andén G, Retinitis pigmentosa: A symposium on terminology and methods of examination, Ophthalmology, 1977;84:956–62.
3. Ikeda Y, Hisatomi T, Yoshida N, et al., The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa, Graefes Arch Clin Exp Ophthalmol, 2012;250:809–14.
4. Fishman GA, Maggiano JM, Fishman M, Foveal lesions seen in retinitis pigmentosa, Arch Ophthalmol, 1977;95:1993–4.
5. Fenkenhour CL, Choromokos E, Weinstein J, et al., Cystoid macular edema in retinitis pigmentosa, Trans Am Acad Ophthalmol Otolaryngol, 1977;83:515–21.
6. Fishman GA, Cutina I, Salani J, Vitreous fluorophotometry in patients with retinitis pigmentosa, Arch Ophthalmol, 1981;99:1320–7.
7. Larsen M, Engler CB, Haim M, et al., Blood retina barrier permeability is independent of trace substance lipid solubility in retinitis pigmentosa and in the healthy eye, Int Ophthalmol, 1998;21:229–34.
8. Mallick KS, Zeimer RC, Fishman GA, et al., Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa, Arch Ophthalmol, 1984;102:691–4.
9. Vintos SA, Kuchle M, Dereujk N, et al., Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization, Histol Histopathol, 1995;10:19–23.
10. Kuchle M, Nguyen NX, Schalmus R, et al., Quantification of disorders of the blood-aqueous humor barrier in retinitis pigmentosa – initial results, Klin Monbl Augenheilkd, 1994;204:211–6.
11. Cox SK, Hay E, Bird AC, Treatment of chronic macular edema with acetazolamide, Arch Ophthalmol, 1998;106:1190–3.
12. Spalten DJ, Bird AC, Cibis PE, Retinitis pigmentosa and retinal oedema, Br J Ophthalmol, 1978;62:174–82.
13. Colson JB, Heyder JK, Söker A, et al., Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy, Am J Ophthalmol, 2001;131:468–71.
14. Mostreifigs DM, Kaster PK, Scott IU, et al., Acute endophthalmitis following intravitreal triamcinolone acetonide injection, Am J Ophthalmol, 2003;136:791–6.
15. Roth BL, Chen H, Spri M, et al., Noninfectious endophthalmitis associated with intravitreal triamcinolone injection, Arch Ophthalmol, 2003;121:1279–82.
16. Pernold P, Wen L, Madigan MC, et al., Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration, Curr Eye Res, 2000;24:499–504.
17. Mansour AM, Shereef H, Kuskentzermer C, et al., Intravitreal dexamethasone implant in patients with late stage cystoid macular edema, Retina 2017. doi: 10.1097/IAE.0000000000015422. (Epub ahead of print).
18. Satoara VS, Salam AN, Panah ME, Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide, Ophthalmic Surg Lasers Imaging, 2003;34:98–400.
19. Oderm H, Katsocou M, Katsocou S, Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa, Acta Ophthalmol Scand, 2006;85:248–51.
20. Wang C, Hu J, Bernstein PN, et al., Intravitreal injection of triamcinolone acetonide for macular edema due to retinitis pigmentosa and other retinal diseases, Adv Exp Med Biol, 2006;572:370–8.
21. Sciolli R, Maruna M, Meduri A, et al., Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal bevacizumab, Graefes Arch Clin Exp Ophthalmol, 2012;249:795–9.
22. Siorou M, Querega Q, Levetel N, et al., Intravitreal dexamethasone implant (Lucentis) for macular edema secondary to retinitis pigmentosa, Graefes Arch Clin Exp Ophthalmol, 2013;251:1501–6.
23. Sato AO, Siever CB, Seymenoglu G, et al., Bilateral intravitreal dexamethasone implant for bilateral cystoid macular edema, Case Rep Ophthalmol, 2013;4:53–8.
24. Alward M, Qazi YJ, Intravitreal dexamethasone implant for bilateral retinitis pigmentosa related macular edema, Graefes Arch Clin Exp Ophthalmol, 2013;251:2827–9.
25. Ahi S, Kim MS, Woo SJ, et al., The effect of an intravitreal dexamethason implant for cystoid macular edema in retinitis pigmentosa - a case report and literature review, Ophthalmic Surg Lasers Imaging Retina, 2014;45:60–4.
26. Örnek N, Öztürk K, Uğurluç E, Intravitreal dexamethasone implant (Lucentis) for inflammatory macular edema secondary to retinitis pigmentosa, Turk J Ophthalmol, 2016;46:179–81.
27. Deissler H, Deisser O, Lang S, et al., VEGF-induced effects on proliferation, migration and light junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells, Br J Ophthalmol, 2008;92:839–43.
28. Nguyen QD, Talipinar S, Shah SM, et al., Vascular endothelial growth factor is a critical stimulus for diabetic macular edema, Am J Ophthalmol, 2006;142:661–9.
29. Salomo D, Diaz Loppis M, Garcia-Delpech S, et al., Aqueous humor levels of vascular endothelial growth factor in retinitis pigmentosa, Invest Ophthalmol Vis Sci, 2008;49:3499–502.
30. Strong SA, Gubisavari A, Michaelides M, Treatment of retinitis pigmentosa-associated cystoid macular oedema using intravitreal aflibercept (Iluvien) despite minimal response to ranibizumab (Lucentis): a case report, Case Rep Ophthalmol, 2016;7:389–97.
31. Melo GB, Panah ME, Aghgo FI, Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa, Acta Ophthalmol Scand, 2007;85:611–3.
32. Yuzbashoglu E, Arunsoy G, Rasier R, et al., Intravitreal bevacizumab (avastin) injection in retinitis pigmentosa, Case Rep Ophthalmol, 2014;5:290–4.
33. Querques G, Prascin F, Iaculli C, et al., Intravitreal pegaptanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa, Br J Ophthalmol, 2009;93:103–7.
34. Ariturky G, Yuzbasoglu E, Rasier R, et al., Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa, J Ocul Pharmacol Ther, 2009;25:545–50.
35. Shah CR, Brem MH, Treatment of retinitis pigmentosa-related cystoid macular edema with intravitreal ranibizumab, Retin Cases Brief Rep, 2010;4:291–3.
36. Moustafta GA, Moschis MM, Intravitreal aflibercept (Iluvien) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature, BMC Ophthalmol, 2015;15:44.
37. Siqueira RC, Messias A, Voltarelli JC, et al., Resolution of macular oedema associated with retinitis pigmentosa after intravitreal use of autologous BM-derived hematopoietic stem cell transplantation, Bike Marrow Transplant, 2013;48:612–3.